TW200733961A - Diaryl urea for treating pulmonary hypertension - Google Patents

Diaryl urea for treating pulmonary hypertension

Info

Publication number
TW200733961A
TW200733961A TW095141431A TW95141431A TW200733961A TW 200733961 A TW200733961 A TW 200733961A TW 095141431 A TW095141431 A TW 095141431A TW 95141431 A TW95141431 A TW 95141431A TW 200733961 A TW200733961 A TW 200733961A
Authority
TW
Taiwan
Prior art keywords
pulmonary hypertension
treating pulmonary
diaryl urea
treating
diaryl
Prior art date
Application number
TW095141431A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Sandner
Hanna Tinel
Joachim Huetter
Bernd Riedl
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of TW200733961A publication Critical patent/TW200733961A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095141431A 2005-11-10 2006-11-09 Diaryl urea for treating pulmonary hypertension TW200733961A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
TW200733961A true TW200733961A (en) 2007-09-16

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095141431A TW200733961A (en) 2005-11-10 2006-11-09 Diaryl urea for treating pulmonary hypertension

Country Status (18)

Country Link
US (1) US20100035888A1 (https=)
EP (1) EP1948170A1 (https=)
JP (1) JP5084736B2 (https=)
KR (1) KR20080067000A (https=)
AR (1) AR057849A1 (https=)
AU (1) AU2006312714A1 (https=)
BR (1) BRPI0618522A2 (https=)
CA (1) CA2628849A1 (https=)
CR (1) CR9953A (https=)
EC (1) ECSP088430A (https=)
GT (1) GT200800058A (https=)
IL (1) IL191178A0 (https=)
NO (1) NO20082498L (https=)
PE (1) PE20070806A1 (https=)
SV (1) SV2009002900A (https=)
TW (1) TW200733961A (https=)
UY (1) UY29903A1 (https=)
WO (1) WO2007054216A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
AU2004212633B2 (en) * 2003-02-21 2010-12-09 ResMed Pty Ltd Nasal assembly
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
DK1797038T3 (da) * 2004-09-29 2012-09-03 Bayer Pharma AG Termodynamisk stabil form af bay 43-9006-tosylat
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
CA2675980C (en) * 2007-01-19 2016-06-21 Bayer Healthcare Llc Use of dast for treatment of cancers with acquired resistance to kit inhibitors
JP2011525503A (ja) * 2008-06-25 2011-09-22 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 心不全を処置するためのジアリールウレア
CN103079567A (zh) * 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7888341B2 (en) * 2002-04-10 2011-02-15 The United States Of America As Represented By The Department Of Veterans Affairs Combination of glivec (STI571) with a cyclin-dependent kinase inhibitor, especially flavopiridol, in the treatment of cancer
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP1850852A4 (en) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center USE OF SILDENAFIL, VARDENAFIL AND OTHER 5-PHOSPHODIESTERASE INHIBITORS TO INCREASE THE PERMEABILITY OF THE ABNORMAL BLOOD-BRAIN DISEASE

Also Published As

Publication number Publication date
WO2007054216A1 (en) 2007-05-18
KR20080067000A (ko) 2008-07-17
AU2006312714A1 (en) 2007-05-18
PE20070806A1 (es) 2007-09-29
CA2628849A1 (en) 2007-05-18
ECSP088430A (es) 2008-07-30
JP5084736B2 (ja) 2012-11-28
AR057849A1 (es) 2007-12-19
BRPI0618522A2 (pt) 2011-09-06
EP1948170A1 (en) 2008-07-30
NO20082498L (no) 2008-08-07
IL191178A0 (en) 2009-08-03
SV2009002900A (es) 2009-04-28
UY29903A1 (es) 2007-06-29
GT200800058A (es) 2010-02-23
US20100035888A1 (en) 2010-02-11
JP2009514910A (ja) 2009-04-09
CR9953A (es) 2008-10-08

Similar Documents

Publication Publication Date Title
TW200733961A (en) Diaryl urea for treating pulmonary hypertension
MY144860A (en) Diaryl ureas for treating pulmonary hypertension
MX2007002397A (es) Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos.
EA200702198A1 (ru) Фармацевтические составы
MX2009006055A (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxam il)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoi co.
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
ATE537828T1 (de) Psychotropes mittel und nahrungsmittel zur förderung der gesundheit enthaltend neferin
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
DE60221510D1 (de) Das nk1 fragment des hepatocytwachstumfaktors/dispersionsfaktors (hgf/sf), varianten davon und deren verwendung
UA87841C2 (ru) Композиция, которая содержит амброксол, для местного применения
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
MX2010001243A (es) Composicion anti-inflamatoria.
WO2010123956A3 (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
BRPI0514269A (pt) compostos heterocìclicos como agentes farmacêuticos
PL1979521T3 (pl) Nowy sposób impregnowania powierzchni tekstylnych
TW200800993A (en) Organic compounds
MX2010014441A (es) Diaril ureas para tratar la insuficiencia cardiaca.
ATE469635T1 (de) Haarbehandlungszusammensetzungen
UA91385C2 (ru) Диарилмочевина для лечения легочной гипертензии
FR2911278B1 (fr) Procede d'obtention d'un actif cosmetique depigmentant, principe actif obtenu et compositions l'incluant
WO2007054303A3 (en) Diaryl urea for treating diabetic neuropathy
WO2007027519A3 (en) Compositions and methods for darkening keratinous fibers
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.
WO2007002093A3 (en) Ansamycin formulations and methods of use thereof
WO2004006900A3 (en) Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases